Why the study?
Does combination therapy with amlodipine and RAAS blockers improve endothelial function compared to monotherapy in patients with hypertension?
Does combination therapy with amlodipine and RAAS blockers improve endothelial function compared to monotherapy in patients with hypertension?
Combination therapy with amlodipine and RAAS blockers may offer additive benefits on endothelial function beyond blood pressure lowering in hypertensive patients.
Hypertension is characterized by endothelial dysfunction and increased risk for adverse cardiovascular outcomes. In addition to lowering blood pressure, the calcium-channel blocker amlodipine and blockers of the renin-angiotensin-aldosterone system (angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor blockers) may further reduce cardiovascular risk by improving endothelial function when used alone or in combination. In fact, the beneficial effects of the combination of amlodipine and a renin-angiotensin-aldosterone system blocker on endothelial function have been found to be greater than the effect of either drug alone, likely due to additive effects on nitric oxide activity. This review summarizes the observed effects of these agents on endothelial function and the complementary mechanisms by which they act, thus providing rationale (beyond blood pressure benefits) for their use in combination.
No takes yet. Share an insight, caveat, or question.
Helmy M. Siragy (2009) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: